<DOC>
	<DOCNO>NCT01982409</DOCNO>
	<brief_summary>The purpose study observe persistence protection , duration protection , safety breakthrough infection rate afford live attenuated varicella vaccine child 5-year period .</brief_summary>
	<brief_title>Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine Children Vaccine Children</brief_title>
	<detailed_description />
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant healthy child age 16 year , inquire medical history physical examination , meet requirement vaccine trial Parent/legal acceptable representative willing able understand protocol requirement provide informed consent Subject parent/guardian able attend schedule visit comply trial procedure Body temperature ≤37℃ Participant previous history chickenpox zoster Receipt varicella vaccine Reported family history allergy , convulsion , epilepsy mental illness Known allergy constituent vaccine Known serve illness , fever , acute infection chronic disease activity Receipt steroid Reported history thrombocytopenia coagulation disorder , may cause Known suspected impairment immunologic function , receipt immunosuppressive therapy immunoglobulin since birth Known congenital malformation , developmental disorder severe chronic disease ( e.g . Down 's syndrome , diabetes , sickle cell anemia neurologic disorder ) Known dermatopathy allergy , herpes , fester , fungal infection Receipt whole blood , blood plasma immunoglobulin 3 month precede trial vaccination Reported history acute illness need systemic antibiotic antiviral treatment infection 7 day precede trial vaccination Participant fever ( temperature≥ 38℃ ) day Any condition , , opinion investigator , would pose health risk subject</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>